---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-043654"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-09-22T12:30:39+00:00"
generated_at: "2026-09-22T12:35:13.427512+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity presents CyPath Lung data at NAVREF 2026; cites 92% sensitivity in veteran study

## Summary
- Two posters presented Sept 27-30, 2026 in Arlington, VA: one on 3 clinical cases, one on FlowPath Lung study.
- FlowPath Lung: 2,000-patient longitudinal study in veterans/military, enrolling at 12 VA centers and 2 military hospitals.
- CyPath Lung reported 92% sensitivity, 87% specificity, 99% NPV for pulmonary nodules ≤20 mm.
- Poster cites 2024 economic analysis projecting hundreds of millions in potential VA screening savings.
- Company appears with new distribution partner AvMEDICAL at first joint federal healthcare market engagement.

## SEC filing metadata
- accession: 0001493152-26-043654
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-09-22T12:30:39+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226043654/0001493152-26-043654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226043654/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-043654
- JSON: https://secwatch.observer/filing/0001493152-26-043654.json
- Plain text: https://secwatch.observer/filing/0001493152-26-043654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.